About this Research Topic
Solid tumors across various systems, including but not limited to the respiratory system, digestive system, urinary system, gynecologic system and ect, represent a significant portion of adult oncology cases. These tumors have complex etiologies and varied genetic and immunological underpinnings. Understanding the genetic and immunological basis of these cancers is crucial for elucidating the mechanisms behind tumor development and progression, and for developing targeted treatments.
Recent advancements in genomic and immunological technologies have enabled researchers to identify specific genetic factors and immune biomarkers that predispose individuals to these solid tumors. For instance, variations in genes involved in cell cycle regulation, apoptosis, and DNA repair have been linked to these cancers. Mutations in oncogenes and tumor suppressor genes such as TP53, KRAS, EGFR, BRAF, and ALK, among others, play pivotal roles in the pathogenesis of these malignancies. Additionally, immune biomarkers such as PD-L1, CTLA-4, and tumor-infiltrating lymphocytes have become critical in understanding the tumor microenvironment and predicting responses to immunotherapy. Recent studies have also highlighted novel targets and biomarkers such as NTRK fusions, RET alterations, and MET exon 14 skipping mutations.
Understanding the genetics and immunology of solid tumors not only aids in predicting susceptibility and disease progression but also enhances the potential for personalized medicine. By tailoring treatment based on an individual's unique genetic and immunological profile, healthcare providers can optimize therapeutic outcomes, minimize adverse effects, and improve quality of life. Moreover, genetic and immunological insights are also paving the way for novel therapies that specifically target the molecular and immune pathways involved in these cancers, offering hope for more effective and less invasive treatment options in the future.
The overarching goal of this Research Topic is to provide a comprehensive, contemporary collection of research focusing on the genetics and immunology of solid tumors in various systems, such as the respiratory system, digestive system, urinary system, gynecologic system and ect. We welcome Original Research Articles, Reviews, Mini Reviews, Systematic Reviews, Perspectives, Commentaries, Data notes, and technical notes, but are not limited to the following:
·Gene Identification: Identifying specific genes that predispose individuals to solid tumors across different systems.
·Biomarkers: Exploring current potential invasive and non-invasive biomarkers to diagnose solid tumors, including genetic and immune biomarkers.
·Diagnosis and Prognosis: Assessing the long-term prognosis of patients with these cancers, considering the availability of new treatment options.
·Personalized Medicine: Applying genetic and immunological information to predict disease susceptibility and progression in individual patients.
·Therapeutic Target Discovery: Using genetic and immunological insights to identify new therapeutic targets, leading to the development of novel treatments that specifically modulate tumorigenic and immune pathways, aiming to treat or even prevent the onset of these cancers.
·Immunotherapy: Investigating the role of immune checkpoint inhibitors, cancer vaccines, and adoptive cell therapies in the treatment of solid tumors.
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
Recent advancements in genomic and immunological technologies have enabled researchers to identify specific genetic factors and immune biomarkers that predispose individuals to these solid tumors. For instance, variations in genes involved in cell cycle regulation, apoptosis, and DNA repair have been linked to these cancers. Mutations in oncogenes and tumor suppressor genes such as TP53, KRAS, EGFR, BRAF, and ALK, among others, play pivotal roles in the pathogenesis of these malignancies. Additionally, immune biomarkers such as PD-L1, CTLA-4, and tumor-infiltrating lymphocytes have become critical in understanding the tumor microenvironment and predicting responses to immunotherapy. Recent studies have also highlighted novel targets and biomarkers such as NTRK fusions, RET alterations, and MET exon 14 skipping mutations.
Understanding the genetics and immunology of solid tumors not only aids in predicting susceptibility and disease progression but also enhances the potential for personalized medicine. By tailoring treatment based on an individual's unique genetic and immunological profile, healthcare providers can optimize therapeutic outcomes, minimize adverse effects, and improve quality of life. Moreover, genetic and immunological insights are also paving the way for novel therapies that specifically target the molecular and immune pathways involved in these cancers, offering hope for more effective and less invasive treatment options in the future.
The overarching goal of this Research Topic is to provide a comprehensive, contemporary collection of research focusing on the genetics and immunology of solid tumors in various systems, such as the respiratory system, digestive system, urinary system, gynecologic system and ect. We welcome Original Research Articles, Reviews, Mini Reviews, Systematic Reviews, Perspectives, Commentaries, Data notes, and technical notes, but are not limited to the following:
·Gene Identification: Identifying specific genes that predispose individuals to solid tumors across different systems.
·Biomarkers: Exploring current potential invasive and non-invasive biomarkers to diagnose solid tumors, including genetic and immune biomarkers.
·Diagnosis and Prognosis: Assessing the long-term prognosis of patients with these cancers, considering the availability of new treatment options.
·Personalized Medicine: Applying genetic and immunological information to predict disease susceptibility and progression in individual patients.
·Therapeutic Target Discovery: Using genetic and immunological insights to identify new therapeutic targets, leading to the development of novel treatments that specifically modulate tumorigenic and immune pathways, aiming to treat or even prevent the onset of these cancers.
·Immunotherapy: Investigating the role of immune checkpoint inhibitors, cancer vaccines, and adoptive cell therapies in the treatment of solid tumors.
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
Keywords: Solid Tumors, Tumor Suppressor Genes, Biomarkers, Immunotherapy, Personalized Medicine
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
